International Stem Cell Corporation (ISCO.OB), www.internationalstemcell.com,
today announced that several of its senior scientists, led by Dr. Ruslan
Semechkin Vice President Research and Development, will present the
results of their most recent experiments on the therapeutic use of human
parthenogenetic stem cells (hpSCs) in Parkinson's disease at the 64th
Annual Meeting of American Academy of Neurology in New Orleans (April 21
to 28 2012).
The data presented at the conference represents progress made in ISCO's
Parkinson's disease program, the successful use of functional
dopaminergic neurons and the results of pre-clinical studies in rodents.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells and the development and
commercialization of cell-based research and cosmetic products. ISCO's
core technology, parthenogenesis, results in the creation of pluripotent
human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenic, homozygous stem
cell line that can be a source of therapeutic cells with minimal immune
rejection after transplantation into hundreds of millions of individuals
of differing genders, ages and racial background. This offers the
potential to create the first true stem cell bank, UniStemCell™. ISCO
also produces and markets specialized cells and growth media for
therapeutic research worldwide through its subsidiary Lifeline Cell
Technology, and cell-based skin care products through its subsidiary
Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, the potential
benefits of research programs and products, and other opportunities for
the company and its subsidiaries, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products and the management of
collaborations, regulatory approvals, need and ability to obtain future
capital, application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update forward-looking statements.
International Stem Cell Corporation:
Ruslan Semechkin, PhD
Vice
President Research and Development
760-940-6383
ras@intlstemcell.com
or
Investor
Relations:
MZ Group
Mark McPartland
Senior Vice President
212-301-7130
markmcp@mzgroup.us
www.mz-ir.com